SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
ABCL

AbCellera Biologics Inc. (NASDAQ:ABCL)

CA · Delayed Price · Currency is USD
Healthcare · Biotechnology
$9.69-$0.78 (-7.45%)
 
Market cap
$3.16B
Insider Score
Health Score
Analyst consensus
Listed since
Dec 11, 2020
Market Cap$3.16B+176.1%
Revenue (ttm)$67.86M+92.1%
Net Income-$148.29M+13.6%
EPS-$0.48+17.2%
Shares Out326.62M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume4,235,023
Open$9.99
Previous Close$10.47
Day's Range$9.58 - $10.26
52-Week Range$2.75 - $15.02
Beta1.19
AnalystsBuy
Price Target$18.20(+87.82%)
Earnings DateFeb 23, 2027

About ABCL

AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.

Address
150 W 4th Ave, Vancouver, BC, V5Y 1G6, CA
Market Cap
3.16 billion
Employees
562
Industrial Classification
Biotechnology

AbCellera Biologics Inc. Stock Analysis — InsiderScore

Insider Score
See top-rated InsiderScore stocks ›
62nd Percentile Overall Score
ABCL InsiderScore:76 / 99

AbCellera Biologics Inc. scored higher than 62% of companies evaluated by InsiderBuying, and ranked 28th out of 101 stocks in the biotech sector.

Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.

Dollars Committed

Insiders at AbCellera Biologics Inc. bought $667.9K of stock across 2 purchases in the last 90 days, the largest of them $570.4K.

Stake Increase

The average purchase added about 2% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.

New Positions

Every buyer already held stock, so each purchase is an increase rather than a first position.

This category carries 35% of the Insider Score.

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$0
Bought
$3.47M

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
2 Buy0 Hold0 SellAvg target $21.00 (+89.7%)

2 firms rating ABCL in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Fair
From ABCL’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-7.45%
5 Days
-13.71%
1 Month
-20.83%
6 Months
+88.52%
1 Year
+176.07%

$ABCL stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in ABCL holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by ABCL's directors and management

Net Shares Purchased by Insiders−300k−150k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

ABCL Estimated quarterly lobbying spending

Source: U.S. Senate LDA

ABCL Revenue by Segment or Geography

ABCL's latest filing doesn't break out revenue by segment.

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New ABCL patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to ABCL from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in ABCL

IBBiShares Biotechnology ETF$20.24M
IDNAiShares Genomics Immunology and Healthcare ETF$7.64M
SPDWState Street SPDR Portfolio Developed World ex-US ETF$6.27M
FKOFirst Trust South Korea AlphaDEX Fund$4.20M
FHKFirst Trust Hong Kong AlphaDEX Fund$4.20M
FDTFirst Trust Developed Markets ex-US AlphaDEX Fund$4.20M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from ABCL’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
70.06
Analyst Ratings
32% of score
99
News & Sentiment
20% of score
72

News check: AbCellera Q3 results showed revenue beats, narrowing losses, and promising hot flash trial advancement toward Phase 3, signaling positive clinical and financial momentum.

Recent Insider Activity

Buys
11
Sells
0
Buy Value
$3.47M
Distinct Buyers
4

Insider Score Trend Over Time

-7.2 since Sep 23
0255075100Sep 23 — Insider Score 75.1Sep 24 — Insider Score 74.0Sep 25 — Insider Score 84.3Sep 26 — Insider Score 84.3Sep 27 — Insider Score 84.4Sep 28 — Insider Score 84.3Sep 29 — Insider Score 83.8Sep 30 — Insider Score 83.6Oct 1 — Insider Score 83.2Oct 2 — Insider Score 48.0Oct 3 — Insider Score 82.7Oct 4 — Insider Score 82.8Oct 5 — Insider Score 82.8Oct 6 — Insider Score 82.3Oct 7 — Insider Score 82.0Oct 8 — Insider Score 81.9Oct 9 — Insider Score 81.8Oct 10 — Insider Score 81.4Oct 11 — Insider Score 82.0Oct 12 — Insider Score 82.0Oct 13 — Insider Score 82.0Oct 14 — Insider Score 81.5Oct 15 — Insider Score 81.4Oct 16 — Insider Score 81.0Oct 17 — Insider Score 80.9Oct 18 — Insider Score 81.1Oct 19 — Insider Score 81.1Oct 20 — Insider Score 81.0Oct 21 — Insider Score 81.0Oct 22 — Insider Score 81.0Oct 23 — Insider Score 81.1Oct 24 — Insider Score 81.0Oct 25 — Insider Score 80.7Oct 26 — Insider Score 80.6Oct 27 — Insider Score 80.6Oct 28 — Insider Score 80.6Oct 29 — Insider Score 79.8Oct 30 — Insider Score 78.7Oct 31 — Insider Score 78.5Nov 1 — Insider Score 77.7Nov 2 — Insider Score 77.7Nov 3 — Insider Score 76.6Nov 4 — Insider Score 75.8Nov 5 — Insider Score 75.0Nov 6 — Insider Score 74.0Nov 7 — Insider Score 73.4Nov 8 — Insider Score 73.9Nov 9 — Insider Score 74.1Nov 10 — Insider Score 70.1Nov 11 — Insider Score 69.2Nov 12 — Insider Score 61.4Nov 13 — Insider Score 79.1Nov 14 — Insider Score 78.2Nov 15 — Insider Score 78.3Nov 16 — Insider Score 75.2Nov 17 — Insider Score 75.8Nov 18 — Insider Score 74.4Nov 19 — Insider Score 73.0Nov 20 — Insider Score 68.8Nov 21 — Insider Score 67.9Sep 23Oct 22Nov 21

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

IDNAiShares Genomics Immunology and Healthcare ETF2.45%
NIFEDirexion Fallen Knives ETF2.10%
BBCVirtus Biotech Clinical Trials ETF1.69%
SILXETFMG Prime 2x Daily Junior Silver Miners ETF0.78%
FKOFirst Trust South Korea AlphaDEX Fund0.37%
FAUSFirst Trust Australia AlphaDEX Fund0.37%
FCANFirst Trust Canada AlphaDEX Fund0.37%
FDTFirst Trust Developed Markets ex-US AlphaDEX Fund0.37%
FHKFirst Trust Hong Kong AlphaDEX Fund0.37%
APXHTwo Roads Shared Trust - APEX HealthCare ETF0.25%
IBBQInvesco Nasdaq Biotechnology ETF0.24%
IBBiShares Biotechnology ETF0.20%

Weight is the stock’s share of each fund’s holdings.